Delhi HC clears Zydus to sell biosimilar of BMS cancer drug Nivolumab

Delhi HC clears Zydus to sell biosimilar of BMS cancer drug Nivolumab

The Delhi High Court has permitted Zydus Lifesciences to produce and market a biosimilar cancer drug. This decision comes as the patent for the original drug, Nivolumab, nears its expiration. The court prioritized patient access to affordable treatment. Zydus…

Read Full Article →

📱 Tip: Tap the 🔗 Share icon in Safari and choose Add to Home Screen to install World Trade Factory.
INFINITY AI
Instagram Meta X LinkedIn Whatsapp